Related by context. All words. (Click for frequent words.) 73 Phase Ib II 72 Phase 1a clinical 72 multicenter randomized controlled 72 BRIM3 71 EURIDIS 71 phase IIIb 71 randomized controlled multicenter 71 Phase III randomized controlled 71 relapsed MM 71 Phase Ib clinical 71 REVIVE Diabetes 70 RE LY ® 70 Phase 1b clinical trials 70 phase IIb clinical 70 MERLIN TIMI 70 CIMZIA TM certolizumab pegol 70 multicentre randomized 70 placebo controlled Phase III 70 Renal Cell Carcinoma RCC 70 ANCHOR trial 70 fosbretabulin 70 Randomized Evaluation 70 ToGA 70 phase IIb trial 70 STRIDE PD 70 dose escalation phase 70 Val HeFT 70 MEND CABG 70 multicenter Phase II 69 PSMA ADC 69 YONDELIS 69 randomized blinded 69 CLARITY study 69 Randomized Phase II 69 IMPACT DCM 69 Xelox 69 Proellex TM 69 GOUT 69 CALGB 69 phase IIa clinical 69 recurrent glioblastoma multiforme 69 EMPHASIS HF trial 69 ADVANCE PD 69 Phase IIb III 69 evaluating Actimmune 69 phase Ib clinical 69 ENGAGE AF TIMI 69 Phase Ib IIa 69 thorough QT 68 Phase IIIb clinical 68 multicenter randomized placebo controlled 68 EXPLORE Xa 68 HCV SPRINT 68 Androxal TM 68 MIST II 68 budesonide foam 68 unfractionated heparin UFH 68 Dacogen injection 68 AVOREN 68 phase IIb 68 HCV RESPOND 2 68 Ocrelizumab 68 randomized Phase IIb 68 NATRECOR R 68 INSPIRE Trial Phase III 68 ZACTIMA 68 pharmacokinetic PK study 68 Phase #b/#a clinical 68 number NCT# ClinicalTrials.gov 68 somatostatin analog 68 DEB# 68 double blinded placebo 68 Motesanib 68 NSABP B 68 evaluating REVLIMID 68 Pivotal Phase III 68 OPT CHF 68 dose escalation clinical 68 Prospective Randomized 68 phase IIa 68 MAGE A3 ASCI 68 Cloretazine 68 blinded randomized placebo controlled 68 pivotal bioequivalence 68 PCI ExTRACT TIMI 68 RE LY 67 BR.# 67 BRIM2 67 trastuzumab emtansine T DM1 67 Bayer HealthCare Onyx Pharmaceuticals 67 CLARITY TIMI 67 Temsirolimus 67 eculizumab therapy 67 double blinded randomized 67 BENICAR HCT 67 Acute Decompensated Heart Failure 67 Phase Ib study 67 AVERROES 67 CALGB # [002] 67 riociguat 67 ritonavir boosted lopinavir 67 Phase III multicenter 67 LUMINATE 67 antiretroviral naïve 67 APEX PD 67 placebo controlled clinical 67 multicenter randomized Phase III 67 phase Ib 67 assessing T DM1 67 prospective randomized multicenter 67 stage IIIb IV 67 Tesmilifene 67 PEARL SC 67 ExTRACT TIMI 67 BCIRG 67 desvenlafaxine succinate 67 Clinical Antipsychotic Trials 67 ACUITY trial 67 acyclovir Lauriad R 67 Degarelix 67 Intervention Trial GAIT 67 PrevOnco 67 neratinib 67 Prostate AdenoCarcinoma Treatment 67 EDEMA3 67 multicenter placebo controlled 67 multicenter multinational 67 HBeAg + 67 CYT# potent vascular disrupting 67 multicenter Phase III 67 including eniluracil ADH 67 CARE HF 67 epoetin alpha 67 multicentre prospective 67 confirmatory clinical 67 ENDEAVOR III 67 ThermoDox ® clinical 67 OvaRex MAb 67 PERSEUS 67 ACTIVE W 67 randomized multicenter Phase III 67 Phase III placebo controlled 67 sunitinib malate 67 Oral Fingolimod 66 doxorubicin docetaxel 66 Phase IIIb study 66 ABSORB trial 66 EchoCRT 66 brivaracetam 66 PANVAC VF 66 randomized controlled Phase 66 herpetic keratitis 66 ENESTnd 66 MKC# MKC# PP 66 REMINYL ® 66 oral ridaforolimus 66 Tarceva TM 66 ancrod 66 Acute Ischemic Stroke 66 Teriflunomide 66 ABSORB clinical 66 Zemplar Capsules 66 ALN HPN 66 treatment naive genotype 66 AIR CF1 66 CONQUER OB 66 LUX Lung 66 Cardiotoxicity 66 phase IIb study 66 dose melphalan 66 novel oral anticoagulant 66 Enzastaurin 66 PROSTVAC ® 66 protease inhibitor PI 66 DIRECT Trial 66 prospective nonrandomized 66 GetGoal Phase III 66 NCIC CTG 66 multicenter randomized clinical 66 trastuzumab DM1 T DM1 66 RSD# oral 66 ARCOXIA 66 multicenter Phase 66 TMC# C# 66 Phase IIIb 66 novel VDA molecule 66 ENDEAVOR IV 66 Medidur TM FA 66 dosing cohort 66 evaluating mipomersen 66 metastatic hormone refractory 66 Omacetaxine 66 clinical pharmacology studies 66 Phase IIa trials 66 Candesartan 66 rALLy 66 VITAL Trial 66 intravenous RSD# 66 VNP#M 66 Phase 2a trial 66 Pre RELAX AHF 66 Phase IIB 66 azilsartan medoxomil 66 clazosentan 66 recombinant PSMA vaccine 66 GRNVAC1 66 APTIVUS 66 AA Amyloidosis 66 phase III isavuconazole 66 NO# [002] 66 Xanafide 66 XL# SAR# 66 registrational Phase 66 midstage clinical 66 elotuzumab 66 CEQ# 66 RECORD1 66 GAMMAGARD 66 Raptiva ® 66 ritonavir boosted 66 lexidronam injection 66 mg/m2 cohort 66 interferon gamma 1b 66 Current Controlled Trials 66 Carotid Revascularization Endarterectomy vs. 66 Cleviprex TM clevidipine 66 Matrix Phase 2b 66 doxorubicin cyclophosphamide 66 biologic DMARD 66 Cloretazine ® 66 Achieves Primary Endpoint 65 trastuzumab Herceptin ® 65 Phase III Clinical Trial 65 chemotherapeutic regimen 65 crizotinib PF # 65 basal bolus regimen 65 Pivotal Trial 65 MGd 65 CRLX# 65 Quinamed 65 Phase III Pivotal 65 ARIXTRA R 65 By JENNIFER LEARN 65 Dyloject TM 65 CANCIDAS 65 rALLy clinical trial 65 Hedgehog Pathway Inhibitor 65 recurrent glioma 65 huN# DM1 65 IMPACT IMmunotherapy 65 Betaferon R 65 Sapacitabine 65 rFSH 65 HORIZONS AMI trial 65 dosing cohorts 65 ISEL 65 SUCCEED trial 65 Targretin capsules 65 CHAMPION PLATFORM 65 irbesartan 65 randomized multicenter trial 65 Velcade bortezomib 65 GLP toxicology studies 65 ROCKET AF 65 Tumor Response 65 AIM HIGH 65 PRIMO CABG 65 Randomized controlled 65 Phase IIb clinical trials 65 multicenter clinical 65 SPIRIT FIRST 65 TASKi2 65 NOX E# 65 CIMZIA ™ 65 Screening Trial DMIST 65 tramiprosate Alzhemed TM 65 oral rivaroxaban 65 bone marrow reticulin deposition 65 CAPACITY trials 65 miconazole Lauriad ® 65 Afatinib 65 neurologic progression 65 CHARM Added 65 reduce serum phosphate 65 ZOLINZA 65 vidofludimus 65 SUTENT ® 65 ORENCIA ® 65 omacetaxine mepesuccinate 65 CLIRS 65 forodesine 65 Multiple Ascending Dose 65 Decitabine 65 GW# [003] 65 PDE4 inhibitor 65 Pazopanib 65 Phase 1b clinical 65 Randomized Double blind 65 paclitaxel poliglumex 65 Study Evaluating 65 galiximab 65 unstable angina pectoris 65 pharmacokinetic PK 65 CAMMS# 65 Oral NKTR 65 BEXXAR Therapeutic Regimen 65 Nesiritide 65 Glufosfamide 65 Deferiprone 65 Pafuramidine 65 BZA CE 65 Phase III Clinical Trials 65 ALN VSP Phase 65 Fludara ® 65 hypoxia activated prodrug 65 hyperphenylalaninemia HPA due 65 Phase 2b Clinical Trial 65 EXPAREL ™ 65 lenalidomide Revlimid R 65 prospective multicentre 65 CAPRIE 65 bazedoxifene conjugated estrogens 65 LibiGel Phase III 65 ONTARGET 65 HORIZONS AMI 65 ULORIC 65 MVax 65 MKC# MT 65 concurrent ITP 65 placebo controlled Phase 65 recurrent metastatic ovarian cancer 65 Phase III randomized 65 Saxagliptin 65 Pimavanserin 65 randomized Phase III 65 PEG SN# 65 Percutaneous Tibial Nerve Stimulation 65 Phase 2b kidney transplant 65 genotypic resistance 65 comparator arm 65 Fibrillex TM 65 FOLOTYN ® 65 RELOVAIR ™ 65 IIa clinical 65 lorcaserin Phase 65 AERAS-#/Crucell Ad# 65 PFO migraine 65 Phase IIA 65 Tipranavir 64 intradermal injections 64 calculated creatinine clearance 64 Phase lll 64 Bruton tyrosine kinase 64 evaluating satraplatin 64 Randomized Clinical Trial 64 CRMD# 64 Severe Sepsis 64 certolizumab 64 adalimumab Humira 64 Phase #/#a 64 Decompensated Heart Failure 64 PF # [002] 64 alvespimycin 64 Dabigatran etexilate 64 sapacitabine CYC# 64 Phase III Psoriasis 64 IMPACT DCM clinical 64 multicenter phase 64 Pharmacokinetics PK 64 SIMPADICO 64 LymphoStat B belimumab 64 Phase IIb trials 64 REALITY Trial 64 MIVI III 64 metastatic malignant 64 evaluating tivozanib 64 EmbraceAC 64 clevidipine 64 cisplatin gemcitabine 64 Dose Ranging Study 64 prospective randomized placebo 64 prospective multicenter study 64 IIb clinical trial 64 melphalan prednisone 64 brivanib 64 Primary endpoints 64 Digital Mammographic Imaging 64 mertansine 64 Safinamide 64 fluvastatin 64 SNT MC# 64 Torisel 64 Daclizumab 64 ATACAND 64 Trandolapril 64 MADIT 64 ZYBRESTAT fosbretabulin 64 PORxin TM platforms 64 PRECISE trial 64 See CLINICAL PHARMACOLOGY 64 worsening thrombocytopenia 64 blinded randomized 64 placebo controlled clinical trials 64 tesmilifene 64 initiate multicenter 64 Clinicaltrials.gov 64 APPRAISE 64 iniparib BSI 64 controlled multicenter 64 Secondary efficacy endpoints 64 Meta analyzes 64 registrational trial 64 papillary renal cell carcinoma 64 preclinical efficacy 64 dose escalation Phase 64 ularitide 64 retrospective observational study 64 PEGINTRON TM 64 NABTT 64 SinuNase ™ 64 placebo controlled randomized 64 balsalazide tablet 64 Phase IIb Clinical Trial 64 Phase IIa trial 64 substudy 64 PRESEPT 64 vinca alkaloid 64 receptor tyrosine kinase inhibitor 64 Faslodex 64 Thrombolysis 64 erlotinib Tarceva ® 64 Thorough QT 64 Dacogen decitabine 64 LAB CGRP 64 COPERNICUS 64 Raptiva R 64 Zenvia Phase III 64 IMiDs ® compound 64 Certolizumab pegol 64 SYMMETRY trial 64 HPTN 64 pharmacologically active isomer 64 Amrubicin 64 AGILECT R 64 recurrent malignant glioma 64 rFVIIa 64 CATIE AD 64 Combination REOLYSIN R 64 intravesical infusion therapy 64 teriflunomide 64 Subgroup analysis 64 Phase #b/#a trial 64 COSIRA trial 64 plus prednisone 64 candesartan cilexetil 64 tolevamer 64 BrachySil TM 64 TNFerade TM 64 Fondaparinux 64 ECASS 64 Romidepsin 64 Intervention Effectiveness 64 APEX AMI trial 64 IMA# 64 Nexavar sorafenib 64 nucleotide analogue 64 Mg Usa 64 biliary tract cancer 64 Navelbine ® 64 Truvada tablets 64 #mg dosing group 64 ER CHOP 64 phase III ACCLAIM 64 R roscovitine 64 boosted protease inhibitor 64 bevirimat Study 64 antibody MAb 64 ® pioglitazone HCl 64 CLIRS trial 64 non nucleoside inhibitor 64 MADIT II 64 Phase III VISTA 64 demonstrated antitumor activity 64 recurrent metastatic 64 Ranolazine 64 beta 1a 64 landmark ATHENA 64 VELCADE melphalan 64 MKC# 64 Delcath Phase III 64 PEG INTRON R 64 Dalbavancin 64 Solorel 64 trials RCTs 64 APEX AMI 64 Medullary Thyroid Cancer 64 Phase Ib Clinical Trial 64 Phase III metastatic melanoma 64 randomized multicentre 64 Mycophenolate Mofetil 64 DAPT Study 64 sargramostim 64 treatment naïve genotype 64 Pertuzumab 64 AZOR 64 immunomodulatory therapy 64 AVN# Phase 64 randomized multicenter 64 Tolvaptan 64 sitaxsentan 64 unstable angina UA 64 MYCAMINE 64 TYGACIL 64 viral kinetic 64 MVA MUC1 IL2 64 BARACLUDE ® 64 Refractory Angina 64 SPRYCEL ® 64 Pharmacokinetic parameters 64 prospective observational studies 64 Phase III ThermoDox 64 AFREZZA TM 64 PROMACTA CARES 64 ACOMPLIA R 64 echocardiographic parameters 64 Clinical Outcomes Utilizing Revascularization 64 Aryplase 64 CTAP# Capsules 64 HDL Selective Delipidation 64 Epirubicin 64 prospective multicenter 64 Phase 1b trial 64 ARB telmisartan 63 ORENCIA R 63 Phase #b/#a 63 prospective observational cohort 63 TBC# 63 pan HDAC inhibitor 63 Myocardial Infarction Study 63 plus DOXIL 63 HGS# 63 PERSEUS clinical program 63 bepotastine besilate nasal spray 63 OvaRex R 63 argatroban 63 NATRECOR ® 63 Phase Ia 63 relapsed refractory multiple myeloma 63 Perforomist Inhalation Solution 63 SinuNase TM 63 cangrelor 63 Hsp# Inhibitor 63 TASKi3 63 Systemic Sclerosis 63 RhuDex 63 Pemetrexed 63 APTIVUS R 63 Phase 2b study 63 Vicriviroc 63 myelodysplastic myeloproliferative diseases 63 docetaxel Taxotere ® 63 ACOSOG Z# 63 INCB# [001] 63 insulin glulisine 63 vinorelbine tartrate 63 relapsing multiple sclerosis 63 EQUIP OB 63 PRADAXA 63 seliciclib CYC# 63 Recurrent Glioblastoma 63 novel emulsion formulation 63 lorvotuzumab mertansine 63 placebo controlled dose escalation 63 dirucotide MBP# 63 RE MODEL 63 heFH 63 icatibant 63 RIO Lipids 63 PROSTVAC VF 63 PREZISTA r 63 vapreotide acetate 63 Urocortin 2 63 Ozarelix 63 Non Alcoholic Steatohepatitis 63 TG MV 63 dose cohort 63 evaluating carfilzomib 63 XIENCE V Everolimus Eluting 63 Dose escalation 63 abacavir Ziagen 63 elacytarabine 63 EDEMA3 trial 63 plasma kallikrein inhibitor 63 CIMZIA TM 63 Phase 2a clinical 63 LHRH receptor positive 63 albiglutide 63 RhuDex ® 63 Phase Ib 63 PLX STROKE targeting 63 ACTEMRA TM 63 velafermin 63 Pharmacodynamic 63 Denufosol 63 Virulizin ® 63 Hormone Refractory Prostate Cancer 63 PrevOnco ™ 63 abiraterone acetate 63 personalized cellular immunotherapy 63 relapsing remitting MS RRMS 63 Gamunex C 63 kidney urologic 63 sorafenib Nexavar 63 aldosterone antagonists 63 LEUKINE 63 5 fluorouracil leucovorin 63 ADAGIO study 63 Glatiramer Acetate 63 Left Ventricular Dysfunction 63 Aggressive Reduction 63 targeting miR 63 R# #mg BID 63 randomized Phase 2b 63 paclitaxel Taxol R 63 HDAC Inhibitor 63 Randomized Study 63 5 HT2A inverse 63 novel histone deacetylase 63 TO AVOID PREGNANCY WHILE 63 MEND CABG II 63 Vitaxin 63 Septin9 63 multicenter prospective 63 LungAlert TM 63 Angiox ® 63 visceral metastases 63 Aplidin R 63 PRIMO CABG2 63 lumiliximab 63 inhaled treprostinil 63 longitudinal cohort study 63 CURE AF 63 HCD# [002] 63 HCV NS5B polymerase 63 Aflibercept 63 intravenous iv 63 Saforis 63 microtubule inhibitor 63 Meets Primary Endpoint 63 European Sepsis Trial 63 ELACYT 63 include Ischemic Paraplegia 63 Randomized Double Blind 63 AAG geldanamycin analog 63 severe hypercholesterolemia 63 Liraglutide Effect 63 QNEXA ® 63 Prolongs Survival 63 FOLFOX6 chemotherapy regimen 63 CYPHER Stent 63 oral FTY# 63 histone deacetylase HDAC inhibitor 63 retrospective cohort 63 Newly Diagnosed Multiple Myeloma 63 ICON7 63 Tanespimycin 63 aurora kinase 63 PARTNER Trial 63 ACE Inhibitor 63 IL# PE#QQR 63 Deforolimus 63 placebo controlled multicenter 63 refractory chronic lymphocytic 63 TAXUS ATLAS 63 thalidomide Thalomid 63 FOLPI 63 intravenous dosing 63 multicentre randomized controlled 63 TLK# 63 Investigator Initiated 63 Omnitarg 63 Phase 2b clinical trials 63 Serdolect ® 63 NEO3 63 intermittent dosing 63 pertuzumab 63 REVIVE TA 63 Randomized Controlled 63 Initiated Phase 63 REVLIMID lenalidomide 63 RE LY trial 63 Dialysis Outcomes 63 metastatic castration resistant 63 Febuxostat 63 Ixempra 63 ALSYMPCA 63 Echocardiographic 63 PROTEGE 63 SIR Spheres 63 Randomised 63 Cholesterol Levels SPARCL 63 ara C 63 randomized discontinuation 63 agalsidase alfa 63 orally administered inhibitor 63 SPL# Gel vaginal microbicide 63 metastatic GIST 63 Plaque Psoriasis 63 VICTOR E1 63 Femara letrozole 63 p# biomarker 63 Phase III PREGNANT PROCHIEVE 63 symptomatic VTE 63 Serious Adverse Events 63 Testosterone MDTS R 63 APTIVUS r 63 sorafenib tablets 63 CA9 SCAN 63 CLL8 63 #mg q8h 63 Completes Patient Enrollment 63 BioSante LibiGel Phase III 63 trastuzumab DM1 63 Phase III confirmatory 63 Vascugel ® 63 Vectibix panitumumab 63 Proc Am Soc 63 inhaled AAT 63 serotonin norepinephrine reuptake inhibitor 63 ARIXTRA 63 QLT Plug Delivery 63 trial evaluating PRX# 63 AZT zidovudine Retrovir 63 3 registrational trial 63 generation purine nucleoside 63 cardio renal 63 pioglitazone HCl 63 Raloxifene Evaluation MORE 63 MoxDuo IR 63 orally inhaled migraine 63 Hepatocellular Carcinoma HCC 63 serum phosphorous 63 rALLy trial 63 Kahalalide F 63 brand ciclesonide HFA 63 mg administered orally 63 deferiprone 63 Acute Coronary Syndromes ACS 63 Aortic Stenosis 63 CINQUIL 63 Fracture Intervention Trial 63 r hGH 63 Testosterone MDTS ® 63 marketed pegylated interferons 62 Edge STudy 62 Folfox 62 SCIg 62 telomerase therapeutic 62 Non inferiority 62 OvaRex ® MAb 62 lenalidomide Revlimid 62 tigecycline 62 Bosutinib 62 Multicenter Automatic Defibrillator Implantation 62 Ophena TM 62 deCODE AF TM 62 vernakalant hydrochloride 62 subcutaneously administered 62 HF ACTION 62 PREOS R 62 senicapoc 62 Forodesine HCl 62 PLCO 62 6R BH4 62 cathepsin K inhibitor 62 Randomized Phase 62 Celecoxib APC trial 62 Demonstrates Positive 62 MADIT CRT trial 62 Rilonacept 62 demonstrated clinically meaningful 62 Hepatitis C HCV 62 Certolizumab 62 nucleoside analog 62 GRAVITAS trial 62 Phase IIb clinical 62 Alzheimer Disease Cooperative 62 Telintra 62 MYDICAR ® 62 AIR CF2 62 #mg QD [002] 62 II Clinical Trial 62 oxaliplatin Eloxatin 62 metastatic colorectal carcinoma 62 rosuvastatin #mg 62 Placebo Controlled Trial 62 Cloretazine VNP#M 62 Ziprasidone 62 Xeloda ® 62 IV bolus 62 morphometric vertebral fractures 62 interstitial brachytherapy 62 Aplidin 62 AVONEX ® 62 Pivotal Phase II 62 de novo kidney transplant 62 TRA 2P 62 doxorubicin Transdrug ® 62 ACR# ACR# 62 IIa trial 62 Bezielle 62 GERD migraine headaches 62 Golimumab 62 prospective multicenter randomized 62 Embolic Protection Device 62 Unstable Angina 62 UroVysion 62 lintuzumab SGN 62 controlled multicenter Phase 62 UVIDEM 62 paclitaxel Taxol ® 62 Eluting Stent 62 NSABP C 62 Myocet 62 acyclovir Lauriad ® 62 Empatic ™ 62 Patients Treated With 62 investigational antiplatelet agent 62 BRILINTA 62 atypical Hemolytic Uremic Syndrome 62 desvenlafaxine 62 acetonide FA 62 canakinumab 62 Vernakalant 62 8mg/kg 62 TKB# 62 novel orally inhaled 62 prucalopride 62 IMC #B 62 resminostat 62 RhuDex R 62 sunitinib Sutent 62 Acute Myocardial Infarction 62 Stenting Trial CREST 62 sevelamer carbonate 62 non nucleoside HCV 62 mcg linaclotide 62 Oncotype DX colon cancer 62 Bioequivalence 62 hour bronchodilation 62 cytoreductive nephrectomy 62 patientswith 62 prospectively defined 62 Coronary Artery Bypass Graft 62 TELINTRA R 62 Triapine R 62 Liprotamase 62 Edurant 62 NCCTG N# 62 develop HBV reactivation 62 visilizumab 62 SWOG 62 BioNumerik 62 R lenalidomide 62 PRECiSE 62 GENASIS 62 DCVax Brain 62 Pivotal Phase 62 IFN alfa 62 Initiate Phase 62 genotoxicity reproductive toxicology 62 gadobutrol 62 placebo controlled studies 62 Azacitidine 62 Triapine 62 Xcellerated T Cells 62 DermaVir Patch 62 Advaxis Phase 62 Elvitegravir 62 Valdoxan 62 RhuDex TM 62 treat chronic sinusitis 62 AVADO 62 #I TM# 62 ONCONASE R 62 HBeAg negative patients 62 huC# DM4 62 pharmacokinetics PK 62 ORACLE MS 62 HER2 overexpression 62 ritonavir boosted protease inhibitor 62 Cimzia TM 62 regorafenib 62 Ridaforolimus 62 Phase IIIB IV 62 microplasmin Phase III 62 CRp 62 Adjuvant Treatment 62 Zevalin consolidation 62 fosamprenavir 62 TRITON TIMI 62 COMBIVIR 62 Ceplene/IL-2 62 Onrigin TM 62 LANTUS ® 62 evaluable subjects 62 catheter occlusion 62 EGS# 62 EOquin TM phase 62 Fibrin Pad 62 Zenvia ™ 62 Systemic Lupus Erythematosus SLE 62 TEMSO 62 oral dual endothelin 62 Microplasmin 62 Initiates Phase II 62 atazanavir ritonavir 62 dalteparin 62 Alocrest 62 NEVO 62 Relapsing Multiple Sclerosis 62 goserelin 62 Pivotal Clinical Trial 62 q8h 62 metastatic HRPC 62 CytoFabTM 62 Preclinical Models 62 evaluating satraplatin plus 62 Allovectin 7 62 HBeAg negative 62 recurrent GBM 62 FDA APPROVES 62 placebo dexamethasone 62 Androgel R 62 Exherin TM 62 microgram kg 62 Evoltra ® 62 salmeterol fluticasone 62 completely resected 62 MoxDuo TM IR 62 Tykerb lapatinib 62 dose Iluvien 62 PI3K/Akt pathway inhibitor 62 Peginterferon alfa 2b 62 Demonstrates Sustained 62 THALOMID 62 BUPHENYL R 62 antiretroviral naive 62 Arimidex Tamoxifen Alone 62 prospective observational 62 dasatinib Sprycel ® 62 divalproex sodium 62 mg q#h 62 Multicenter Phase 62 PRT# 62 Nebulized 62 First Patient Enrolled 62 EnteroMedics proprietary neuroblocking technology 62 INCB# [003] 62 paclitaxel cisplatin 62 dextofisopam 62 Pivotal Study 62 oral renin inhibitor 62 StemEx 62 CAMPATH 62 mg BID dose 62 Hycamtin ® 62 glycoprotein IIb IIIa inhibitor 62 Myelodysplastic Syndrome MDS 62 prelicensure 62 MelaFind R 62 mITT population 62 chemoradiation therapy 62 Phase 2a Clinical Trial 62 FDA Investigational Device 62 neoadjuvant treatment 62 remission CR 62 plasma pharmacokinetics 62 GSK# [001] 62 BARACLUDE R 62 pharmacokinetic equivalence 62 delivers fluocinolone acetonide FA 62 ritonavir boosted atazanavir 62 Phase III HEAT 62 Prodarsan R 62 indinavir Crixivan 62 Sorafenib HCC Assessment 62 ug dose 62 ACCORD Lipid 62 OncoVex 62 null responder HCV 62 Onrigin 62 HeFT 62 ChronVac C R 62 ELOXATIN 62 Dose Escalation 62 humanised monoclonal antibody 62 Plicera 62 Fractional Flow Reserve